Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

(2020) Eva Schrezenmeier et al.   Nature Reviews Rheumatology

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

(2020) Kimiyasu Shiraki et al.   PHARMACOLOGY & THERAPEUTICS

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

(2020) Yin‐Xiao Du et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Coronavirus Disease 2019 (COVID‐19): What we know?

(2020) Feng He et al.   JOURNAL OF MEDICAL VIROLOGY

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

(2020) Jia Liu et al.   Cell Discovery

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa

(2019) Timothy M Uyeki et al.   CLINICAL INFECTIOUS DISEASES

New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections

(2019) Erik De Clercq   Chemistry-An Asian Journal

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

Dose regimen of favipiravir for Ebola virus disease

(2015) France Mentré et al.   LANCET INFECTIOUS DISEASES